Loading...
Market
What financial actions will Applied Therapeutics take by Nov 30, 2025?
3
Resolution / Starting Odds
Raises additional capital • 25%
Files for bankruptcy • 25%
Merges with another company • 25%
No significant financial actions • 25%
Financial reports, press releases, or major financial news outlets
Story
FDA Issues CRL for Applied Therapeutics' Govorestat, Shares Drop 80%, Trading Halted
Nov 27, 2024, 09:15 PM
Applied Therapeutics Inc. announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the New Drug Application (NDA) of its drug, Govorestat, intended for the treatment of Classic Galactosemia, a rare genetic metabolic disorder. The FDA cited clinical deficiencies in the application, indicating that the submitted data did not meet the primary endpoints and raised concerns about the relevance of the biomarker used in the study. Govorestat, a central nervous system-penetrant aldose reductase inhibitor, was the company’s first potential commercial product. Following the announcement, shares of Applied Therapeutics dropped significantly, declining by 80% during after-hours trading, and trading was temporarily halted. The company holds $0.67 per share in cash. Analysts suggest that the company may need to conduct another Phase 3 trial to address the FDA's concerns, despite a push from patient advocacy groups.
View original story
Similar markets
Significant increase in revenue • 25%
Moderate increase in revenue • 25%
No significant change • 25%
Decrease in revenue • 25%
Above $200 million • 25%
Between $100 million and $200 million • 25%
Between $50 million and $100 million • 25%
Below $50 million • 25%
Launches new product • 25%
Announces partnership • 25%
Pursues merger/acquisition • 25%
No major move • 25%
Acquired by another company • 25%
Forms a major collaboration • 25%
Remains independent • 25%
Other • 25%
Profitable • 25%
Break-even • 25%
Loss-making but stable • 25%
Facing financial distress • 25%
Yes • 50%
No • 50%
Revenue increases by 10% or more • 25%
Revenue stays within 10% of current levels • 25%
Revenue decreases by 10% or more • 25%
Cassava Sciences reports a loss • 25%
Increase Bitcoin holdings • 25%
Invest in another cryptocurrency • 25%
Invest in traditional assets • 25%
No major investment move • 25%
Yes • 50%
No • 50%
